EUCTR2016-003529-41-NL进行中(未招募)1 期
CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia - CANGLIA
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A DSM-IV diagnosis of 295.x (schizophrenia, schizophreniform disorder or schizoaffective disorder) or 298.9 (psychosis NOS). Diagnosis must be confirmed in writing by the treating psychiatrist.
- •Age 16 - 40
- •Onset of first psychosis no longer than five years ago
- •Written informed consent of the subject
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 36
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial
- •Routine laboratory screening values considered an impediment for participation by a medical doctor (see Appendix 1)
- •Positive urine test on any drug of abuse, except cannabis
- •Treatment with more than one antipsychotic agent or with an unstable dose of one type of antipsychotic medication in the month prior to study inclusion
- •Use of glucocorticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks prior to study inclusion
- •Use of co-medication other than antipsychotics that has a clinically relevant interaction with the cytochrome P450 (CYP) 2C19 or CYP3A classes of liver enzymes within two weeks prior to study inclusion (because CBD may be an inhibitor of these classes of liver enzymes; see paragraph 6.3)
- •Intake of investigational drug within one month prior to study inclusion
- •Daily use of alcohol or drugs of abuse (including cannabis) in the three months prior to study inclusion
- •Any current or previous neurological disorder, including epilepsy
- •History of head injury resulting in unconsciousness lasting at least 1 hour
- •IQ < 70, as measured with Dutch version of the National Adult Reading Test (DART)
- •Breastfeeding, pregnancy or attempting to conceive
- •MRI contraindications, e.g. claustrophobia or metal objects in or around the body
研究者
相似试验
已完成
不适用
CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophreniapsychotic disorder10039628schizophreniaNL-OMON47069Psychiatrie20
已完成
不适用
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of SchizophreniaSchizophreniaNCT02932605UMC Utrecht32
撤回
不适用
The role of the endocannabinoid system in Attention-Deficit/Hyperactivity Disorder and symptoms: a pharmacological fMRI studyADHDAttention-Deficit/Hyperactivity Disorder10037176NL-OMON35106niversitair Medisch Centrum Utrecht24
招募中
不适用
Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study (for smoker)schizophreniaJPRN-UMIN000038171Hamamatsu University Hospital20
已完成
早期 1 期
CBD-Microglia PET StudyCBDHealthyNCT04398719Yale University28
